Evidence map›Paper›PMID 31407168›Full record

ReviewInternational journal of clinical oncology2020

Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.

Ryoichi Saito, Takashi Kobayashi, Soki Kashima, Keiyu Matsumoto, Osamu Ogawa

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. [Efficacy of CD4/TGF-β bispecific antibody in a mouse model of peritoneal metastasis of malignant melanoma].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ryoichi SaitoDepartment of Urology, Kyoto University, Kyoto, Japan. rsaito@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-3163-8723
Takashi KobayashiDepartment of Urology, Kyoto University, Kyoto, Japan.
Soki KashimaDepartment of Urology, Kyoto University, Kyoto, Japan.
Keiyu MatsumotoDepartment of Urology, Kyoto University, Kyoto, Japan.
Osamu OgawaDepartment of Urology, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers. Here we review the advantages and disadvantages of current preclinical mouse models, including syngeneic murine tumor cell lines, autochthonous tumor models, cancer cell line-derived xenografts, patient-derived-xenografts, and various kinds of immunologically humanized mice. We discuss how these models should be characterized and applied in preclinical settings, and how we should prepare preclinical studies for successful translation from bench to bedside.

Indexed as

ImmunotherapyAnimalsCell Line, TumorHumansMiceNeoplasms, ExperimentalTranslational Research, BiomedicalVertebratesXenograft Model Antitumor AssaysHumanized mouseImmune checkpoint inhibitorImmunotherapyMouse cancer modelPreclinical studySyngeneic cell line

Identifiers

PMID31407168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.